All coverage of this event, automatically grouped from multiple independent sources.
Last updated: 8 September 2026 at 13:56 · 7 articles · 2 sources
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.
Read at CNBC · 8 September 2026 at 13:36
Sandoz CEO Richard Saynor warns steep U.S. tariffs on imported generic drugs could force manufacturers to raise prices or cut supply.
Read at CNBC · 8 September 2026 at 13:31
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
Read at CNBC · 8 September 2026 at 13:26
These positive results could open up a new way to treat serious lung disease.
Read at STAT News · 8 September 2026 at 10:00
When the FDA approved a new pancreatic cancer drug called Rasonque, researchers celebrated. But some patients hoping for quick access have been stymied.
Read at STAT News · 8 September 2026 at 08:30
A Novartis drug for a rare neuromuscular condition failed in a key study, the company's second major trial collapse in a matter of days.
Read at STAT News · 8 September 2026 at 07:28
Novartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer heart attacks and strokes.
Read at CNBC · 8 September 2026 at 05:00